Fig. 2From: Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancera ROC curve of the diagnosis study, using a logistic regression analysis based on presence/absence of FGFR3 mutation and the CMI of HS3ST2, SEPTIN9, and SLIT2. b ROC curve for the recurrence study, using a logistic regression analysis based on FGFR3 mutation CMI_t and CMI_0Back to article page